MSX-122 is a novel, potent and orally bioavailable inhibitor/partial antagonist of CXCR4 which inhibits CXCR4/CXCL12 actions with an IC50 of 10 nM. It has potential anticancer and antiviral activities. MSX-122 acts by binding to CXCR4, thus preventing its interaction with stromal derived factor-1 (SDF-1), leading to decreased tumor cell proliferation and migration.

纯度：≥98%

CAS：897657-95-3